PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23314867-1	2013	To design a releasable PEGylated TNF-alpha (rPEG-TNF-alpha), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF-alpha (PEG-TNF-alpha), facilitating its clinical use for anti-tumor therapy.	Dipeptides	85-94	tumor necrosis factor	Mus musculus	33-42	
25225121-7	2014	KEY FINDINGS: All the tested dipeptides significantly inhibited the secretion of nitric oxide, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 from LPS-stimulated RAW 264.7 macrophages.	Dipeptides	29-39	tumor necrosis factor	Mus musculus	95-128	
23314867-1	2013	To design a releasable PEGylated TNF-alpha (rPEG-TNF-alpha), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF-alpha (PEG-TNF-alpha), facilitating its clinical use for anti-tumor therapy.	Dipeptides	85-94	tumor necrosis factor	Mus musculus	49-58	
23314867-1	2013	To design a releasable PEGylated TNF-alpha (rPEG-TNF-alpha), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF-alpha (PEG-TNF-alpha), facilitating its clinical use for anti-tumor therapy.	Dipeptides	85-94	tumor necrosis factor	Mus musculus	49-58	
23314867-1	2013	To design a releasable PEGylated TNF-alpha (rPEG-TNF-alpha), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF-alpha (PEG-TNF-alpha), facilitating its clinical use for anti-tumor therapy.	Dipeptides	85-94	tumor necrosis factor	Mus musculus	49-58	
9301110-3	1997	Oral administration of PLE also inhibited TNF-alpha production that was induced by muramyl dipeptide (500 micrograms/mouse) and OK-432 (3 KE/mouse).	Dipeptides	91-100	tumor necrosis factor	Mus musculus	42-51	
21318482-0	2011	Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-alpha) against murine fibrosarcoma.	Dipeptides	35-44	tumor necrosis factor	Mus musculus	112-139	
21318482-0	2011	Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-alpha) against murine fibrosarcoma.	Dipeptides	35-44	tumor necrosis factor	Mus musculus	141-150	
21318482-1	2011	To improve the pharmacological profile of tumor necrosis factor alpha (TNF-alpha), we have synthesized a new PEGylated prodrug, PEG-vcTNF-alpha, using a cathepsin B-sensitive dipeptide (valine-citrulline, vc) to link branched PEG and TNF-alpha.	Dipeptides	175-184	tumor necrosis factor	Mus musculus	42-69	
21318482-1	2011	To improve the pharmacological profile of tumor necrosis factor alpha (TNF-alpha), we have synthesized a new PEGylated prodrug, PEG-vcTNF-alpha, using a cathepsin B-sensitive dipeptide (valine-citrulline, vc) to link branched PEG and TNF-alpha.	Dipeptides	175-184	tumor necrosis factor	Mus musculus	71-80	
21318482-1	2011	To improve the pharmacological profile of tumor necrosis factor alpha (TNF-alpha), we have synthesized a new PEGylated prodrug, PEG-vcTNF-alpha, using a cathepsin B-sensitive dipeptide (valine-citrulline, vc) to link branched PEG and TNF-alpha.	Dipeptides	175-184	tumor necrosis factor	Mus musculus	134-143	
11367521-0	2001	Induction of tumor necrosis factor-alpha in solid tumor region by the orally administered synthetic muramyl dipeptide analogue, romurtide.	Dipeptides	108-117	tumor necrosis factor	Mus musculus	13-40	
2036659-2	1991	Lipid A and especially its combination with muramyl dipeptide induced high TNF levels in Swiss mice, as measured in the serum.	Dipeptides	52-61	tumor necrosis factor	Mus musculus	75-78